COMMUNIQUÉS West-GlobeNewswire

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
13/08/2026
SYMON-II pivotal clinical study completes targeted enrollment of 750 patients Company advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain risk [...]
Vistin Pharma ASA: Invitation to Q2 2026 conference call
13/08/2026
Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other [...]
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13/08/2026
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and [...]
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
13/08/2026
Ventes totales de produits de 64,0 millions d’euros o En ligne avec les attentes ; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d’euros. Solide position de trésorerie de 121,5 [...]
Zealand Pharma Announces Financial Results for the First Half of 2026
13/08/2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum [...]
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08/2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan [...]
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 [...]
Range Impact Reports 2Q 2026 Financial Results
12/08/2026
CLEVELAND, OHIO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming, and redeveloping legacy coal mines throughout [...]
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
12/08/2026
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 [...]
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
12/08/2026
Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy [...]
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
12/08/2026
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and [...]
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
Added 3 top-rated children’s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical [...]
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway [...]
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 [...]
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
12/08/2026
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation Single and multiple ascending doses planned Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026 [...]
MaxCyte Reports Second Quarter 2026 Financial Results
12/08/2026
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $ [...]
Lumexa Imaging Announces Second Quarter 2026 Results
12/08/2026
RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, [...]
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
12/08/2026
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III [...]
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
12/08/2026
SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]

Pages